10-K: Cognition Therapeutics Reports 2025 Results, Advances Zervimesine

Cognition Therapeutics, a clinical-stage biopharmaceutical company, reported its 2025 annual results, highlighting progress in its zervimesine clinical programs for Alzheimer's and Lewy body dementia, while facing continued net losses and capital needs.

Summary

• Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative diseases of the central nervous system and retina.
• The lead product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of pathogenic protein oligomers (Aβ-amyloid and α-synuclein).
• Zervimesine has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for Alzheimer's disease (AD).
• The Phase 2 COG0201 (SHINE) study in mild-to-moderate AD completed in 2024, reporting top-line results in July 2024 and additional data in October 2024, showing a cognitive benefit and a 95% reduction of cognitive decline in patients with lower plasma p-tau217 at baseline.
• Enrollment for the Phase 2 COG0203 (START) study in Mild Cognitive Impairment (MCI) and early-stage AD, involving 545 participants, was completed in December 2025, with top-line results expected after all participants complete 18 months of treatment.
• An end-of-Phase 2 meeting with the FDA in July 2025 for the SHINE study resulted in FDA concurrence with the proposed Phase 3 plan, which includes randomizing participants to 100 mg of oral zervimesine daily for at least six months and enriching the study population with AD patients having lower plasma p-tau217 at screening.
• The European Medicines Agency (EMA) indicated a preference for a longer Phase 3 trial than proposed for AD.
• The Phase 2 COG1201 (SHIMMER) clinical trial in 130 adults with mild-to-moderate Dementia with Lewy Bodies (DLB) concluded in 2024, with top-line results presented in December 2024 and January 2025, showing efficacy signals across behavioral, functional, cognitive, and motor scales, particularly in hallucinations and delusions.
• Based on FDA feedback from a Type C meeting in January 2026, the company plans to develop zervimesine for DLB psychosis.
• An Expanded Access Program (COG1202 EAP) for DLB patients was initiated in June 2025, enrolling 32 eligible participants, with enrollment concluding in December 2025.
• The Phase 2 COG2201 (MAGNIFY) study for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) was voluntarily concluded in January 2025, after enrolling 100 participants, to focus resources on dementia programs, despite showing zervimesine slowed GA lesion growth rates by 29% compared to placebo.
• The company reported a net loss of $23.5 million for the year ended December 31, 2025, an improvement from a $34.0 million net loss in 2024, with an accumulated deficit of $198.6 million as of December 31, 2025.
• Cash, cash equivalents, and restricted cash equivalents totaled $37.0 million as of December 31, 2025.
• Cumulative non-dilutive grants, primarily from the National Institute on Aging (NIA), amount to approximately $171 million, with $35.7 million available from NIA funds as of October 15, 2025.
• In August 2025, the company completed a registered direct offering, issuing 14,700,000 shares of common stock at $2.05 per share, generating net proceeds of approximately $27.9 million, and issued warrants to the placement agent for 514,500 shares at an exercise price of $2.78.
• A new at-the-market (ATM) offering program (2025 ATM) for up to $75 million of common stock was filed in December 2025, with no sales as of December 31, 2025.
• The Lincoln Park Purchase Agreement, which allowed for the sale of up to $35.0 million in common stock, expired on March 10, 2026, with $34.8 million available but unused as of December 31, 2025.
• Existing capital and grant income are projected to fund operations through the second quarter of 2027, but substantial additional funding will be required for regulatory approval and commercialization.
• The company's intellectual property portfolio includes ten issued U.S. patents and forty-five issued foreign patents, with the zervimesine composition of matter patent naturally expiring in 2035, subject to potential extensions.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed filing. While clinical data for zervimesine in AD and DLB show promising efficacy signals and the company has secured significant non-dilutive funding, the persistent net losses, substantial accumulated deficit, and explicit need for significant additional capital for regulatory approval and commercialization indicate ongoing financial challenges and high operational risk. The strategic discontinuation of the AMD program, despite positive results, underscores resource constraints.

Positives

• Zervimesine received Fast Track designation by the U.S. FDA for Alzheimer's disease, potentially expediting its development and review.
• The Phase 2 SHINE study in mild-to-moderate AD demonstrated a cognitive benefit, with a 95% reduction of cognitive decline in patients with lower plasma p-tau217 at baseline, suggesting a potential responder population.
• The Phase 2 SHIMMER study in DLB showed promising efficacy signals across behavioral, functional, cognitive, and motor scales, with notable treatment effects observed in hallucinations and delusions, addressing a significant unmet medical need.
• Zervimesine has consistently shown a generally well-tolerated safety profile across clinical trials, with 782 subjects having received the drug.
• Preclinical studies successfully demonstrated zervimesine's mechanism of action in preventing Aβ and α-synuclein oligomer binding and restoring functional capabilities in AD mouse models.
• The company has secured approximately $171 million in cumulative non-dilutive grants, primarily from the NIA, significantly funding its clinical trials and reducing reliance on dilutive capital.
• The company retains all worldwide rights to zervimesine for all indications, providing full control over its commercial potential.
• A robust intellectual property portfolio includes ten issued U.S. patents and forty-five issued foreign patents, with the zervimesine composition of matter patent projected to expire no earlier than 2035 and eligible for up to five years of Patent Term Extension (PTE).
• The management team possesses extensive experience in CNS and degenerative diseases, drug discovery, clinical development, and regulatory approval, enhancing the company's strategic capabilities.

Negatives

• The company incurred significant net losses of $23.5 million in 2025 and $34.0 million in 2024, contributing to a substantial accumulated deficit of $198.6 million as of December 31, 2025.
• There are no products approved for commercial sale, and the company has no history of commercializing products, indicating a long and uncertain path to profitability.
• The company explicitly expects to incur significant losses for the foreseeable future and may never achieve or maintain profitability.
• The Phase 2 MAGNIFY study for dry AMD was voluntarily concluded in January 2025, despite favorable results, due to a strategic decision to conserve company resources, highlighting financial constraints.
• Some participants in higher dose groups of earlier AD trials (COG0102, COG0105, COG0201) experienced asymptomatic, reversible elevations in liver enzymes (LFTs), leading to increased monitoring and some discontinuations.
• The European Medicines Agency (EMA) expressed a preference for a longer Phase 3 trial for AD than proposed, which could potentially delay European regulatory approval.
• The company relies on single third-party contract manufacturers for drug substance and clinical trial supplies, posing supply chain risks if these suppliers fail to comply with regulations or provide sufficient quantities.
• The Lincoln Park Purchase Agreement, which offered up to $35.0 million in equity financing, expired on March 10, 2026, with $34.8 million available but unused as of December 31, 2025, suggesting difficulties in utilizing this capital source.
• The 2022 ATM program was terminated in December 2025, with approximately $12.5 million remaining in gross proceeds available but unused, further indicating challenges in raising capital through this facility.

Risks

• The company will need substantial additional capital to meet future financial obligations and pursue business objectives; inability to raise capital could force curtailment of planned operations and growth strategy.
• Failure to comply or regain compliance with Nasdaq Capital Market listing standards could lead to delisting, negatively impacting stock price and access to capital markets.
• The company is a clinical-stage biopharmaceutical company with no products approved for commercial sale and has incurred significant losses since inception, expecting to incur significant losses for the foreseeable future and may never achieve or maintain profitability.
• Lack of history in commercializing products makes it difficult for investors to evaluate business success and future viability.
• Partial reliance on non-dilutive grants for clinical trial capital requirements; failure to continue receiving such funding or adhere to grant terms could impair clinical programs and necessitate dilutive financing.
• Business is heavily dependent on the successful development, regulatory approval, and commercialization of zervimesine and any future product candidates.
• May not successfully expand the pipeline of product candidates, including pursuing additional indications for zervimesine or in-licensing/acquiring additional candidates.
• Preclinical and clinical development is a lengthy, expensive process with an uncertain outcome, and results of preclinical studies and early clinical trials are not necessarily predictive of future results.
• The company has not tested any product candidates in pivotal clinical trials, and future clinical trials may not have favorable results.
• Inability to obtain and maintain patent protection for technology and product candidates, including zervimesine, or if the scope of protection is not sufficiently broad, could impair competitive effectiveness.
• Inability to protect intellectual property rights throughout the world due to varying legal protections and enforcement.
• Patent terms may be inadequate to protect the competitive position of product candidates, including zervimesine, for an adequate amount of time, potentially leading to generic competition.
• Third-party claims or litigation alleging infringement of patents or other proprietary rights, or seeking to invalidate patents, may delay or prevent the development and commercialization of product candidates.
• Even if current or future product candidates obtain regulatory approval, they may fail to achieve broad adoption and commercial success by physicians, patients, hospitals, and healthcare payors.
• Market opportunities for zervimesine, if approved, may be smaller than anticipated.
• Reliance on single third-party suppliers to manufacture product candidates and commercial supplies; loss or failure of these suppliers could materially and adversely affect business, financial condition, results of operations, and prospects.
• Product candidates have never been manufactured on a commercial scale, and there are risks associated with scaling up manufacturing to commercial scale, which may not be successful.
• Reliance on third parties for the conduct of all clinical trials; if these third parties do not successfully carry out contractual duties, fail to comply with regulatory requirements, or meet expected deadlines, regulatory approval may be unobtainable.
• Significant competition in an environment of rapid technological and scientific change; competitors may achieve regulatory approval before the company or develop superior therapies, negatively impacting marketability and financial condition.
• Even if regulatory approval is obtained for a product candidate, products will remain subject to ongoing regulatory scrutiny and compliance requirements.
• Healthcare legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty and cost for obtaining marketing approval and commercializing product candidates.
• If a small molecule product candidate obtains regulatory approval, additional competitors could enter the market with generic versions, resulting in a material decline in sales.
• The market price and trading volume of common stock have been and may continue to be volatile, which could result in rapid and substantial losses for stockholders.
• Provisions of charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition, even if beneficial to stockholders, and may prevent attempts to replace or remove current management.
• Changes in funding for, or disruptions to the staffing and operations of the FDA and other government agencies could hinder their ability to hire, retain, or deploy key personnel, or otherwise prevent new or modified products from being developed, approved, or commercialized in a timely manner.
• Clinical trials for product candidates are conducted outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials.
• Failure to comply with health and data protection laws and regulations could lead to government enforcement actions, civil or criminal penalties, private litigation, or adverse publicity.
• The use of new and evolving technologies, such as artificial intelligence, in the business may result in risks and challenges, including intellectual property and security risks.
• Employees and independent contractors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have an adverse effect on results of operations.
• Environmental, social, and governance (ESG) matters may impact the business and reputation.
• Ability to use net operating loss carryforwards and other tax attributes may be limited due to ownership change provisions under Sections 382 and 383 of the Code.
• Changes in tax laws and regulations may have a material adverse effect on business, financial condition, and results of operations.
• Subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations; compliance with these legal standards could impair ability to compete and lead to criminal liability.
• Existing regulatory policies may change, and additional government regulations may be enacted that could prevent, limit, or delay regulatory approval of product candidates, including impacts from the U.S. Supreme Court overruling the Chevron doctrine or changes in U.S. federal administration policies.

Future Outlook

The company expects to incur significant and increasing expenses and net losses for the foreseeable future, necessitating substantial additional funding to support continuing operations and its growth strategy. Top-line results for the COG0203 (START) Phase 2 study are anticipated after participants complete 18 months of treatment. The company plans to develop zervimesine for DLB psychosis and will engage with the FDA Division of Psychiatry to align on study design. Strategic elements include evaluating additional product candidates, pursuing non-dilutive funding, and optimizing zervimesine's value in major markets, potentially through collaborations. The company also plans to transition to a larger third-party manufacturer for late-stage clinical and commercial supply and will need to establish its own sales and marketing infrastructure or partner with third parties for commercialization.

Management Comments

• Our goal is to develop disease-modifying treatments for patients with these degenerative disorders.
• We believe our evidence demonstrates that zervimesine displaces Aβ oligomers from their neuronal receptors.
• Based on this mechanism, we believe zervimesine has the potential to slow the loss of synapses and cognitive decline observed in AD.
• Zervimesine has continued to be generally well tolerated.
• Cognition is planning to meet with the FDA Division of Psychiatry to discuss a DLB psychosis program and align on study design.
• FDA concurred with the proposed plan to randomize participants to 100 mg of oral zervimesine or placebo daily for at least six months and to enrich the Phase 3 study population with AD patients who have lower plasma p-tau217 at screening.
• We believe our existing cash and cash equivalents and income from our non-dilutive grants will not be sufficient to fund any of our product candidates through regulatory approval, and we will need to raise substantial additional capital to complete the development and commercialization of zervimesine and our product candidates.
• We believe that our current facilities are adequate to meet our ongoing needs, and that, if we require additional space, we will be able to obtain additional facilities on commercially reasonable terms.
• Our management and other personnel will need to devote a substantial amount of time to ensure that we comply with all of these requirements.

Industry Context

StockSavvy.ai notes that the neurodegenerative disease market, particularly for Alzheimer's and Lewy Body Dementia, remains an area of significant unmet medical need with limited approved disease-modifying therapies. The company's focus on a novel small-molecule approach targeting protein oligomers differentiates it from recently approved monoclonal antibody therapies like Eisai's Leqembi and Eli Lilly's Kisunla, which target Aβ plaques and protofibrils. The discontinuation of Biogen's Aduhelm highlights the challenges and high failure rate in this therapeutic area. The reliance on non-dilutive government grants is a common strategy for early-stage biopharmaceutical companies in high-risk development areas.

Comparison to Industry Standards

• Alzheimer's Disease (AD) Treatments: Cognition Therapeutics' zervimesine, an oral small molecule targeting Aβ oligomer binding, represents a distinct approach compared to currently approved monoclonal antibody therapies like Eisai's Leqembi (approved July 2023) and Eli Lilly's Kisunla (approved July 2024), which focus on reducing Aβ plaques and protofibrils. The discontinuation of Biogen's Aduhelm (approved July 2021, discontinued January 2024) underscores the high failure rate and challenges in this therapeutic area, making zervimesine's positive Phase 2 results notable.
• Dementia with Lewy Bodies (DLB) Treatments: There are currently no FDA-approved disease-modifying therapeutics for DLB. Most antipsychotics approved for other conditions are contraindicated in DLB patients due to severe side effects. Cognition Therapeutics' zervimesine, with its Phase 2 SHIMMER study showing efficacy signals in hallmark psychotic symptoms like hallucinations and delusions, positions it to potentially address a critical unmet need in a market lacking targeted treatments.
• Geographic Atrophy (GA) Secondary to Dry AMD Treatments: While the filing mentions two approved treatments for GA, it does not name them. Cognition Therapeutics' MAGNIFY study, though discontinued for strategic reasons, showed zervimesine slowed GA lesion growth rates by 29% and reduced mean lesion area by 28% compared to placebo. This suggests a potentially competitive efficacy profile against existing therapies, such as complement inhibitors, which have reported conversions to neovascular AMD, a side effect not observed with zervimesine.
• Funding Strategy: The company's success in securing approximately $171 million in cumulative non-dilutive grants, primarily from the NIA, provides a significant advantage compared to many early-stage biopharmaceutical companies that rely predominantly on dilutive equity financing, allowing for sustained research and development without immediate shareholder dilution.

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.
• May, from time to time, become involved in disputes or regulatory inquiries that arise in the ordinary course of business.
• As a public company, potentially susceptible to litigation, such as claims asserting violations of securities laws, which could be costly and time-consuming.

Stakeholder Impact

• Shareholders: Face potential dilution from future equity offerings, stock price volatility, and the absence of dividends. Anti-takeover provisions may limit their influence on corporate control. The need for substantial additional capital poses a risk to their investment.
• Employees: The company aims to attract, retain, incentivize, and integrate employees, with equity and cash incentive plans in place. Expansion will require additional hiring, but also exposes them to risks of misconduct and potential legal claims.
• Patients (future customers): Stand to benefit from the development of disease-modifying treatments for Alzheimer's disease and Dementia with Lewy Bodies, addressing significant unmet medical needs. The Expanded Access Program for DLB patients provides early access to zervimesine.
• Creditors: The company's recurring losses and explicit need for substantial additional funding could impact its creditworthiness and the terms of any future debt financing.
• Suppliers/Manufacturers: The company's reliance on single third-party contract manufacturers creates dependency and risks if these suppliers fail to comply with regulations, meet quality standards, or provide sufficient quantities, potentially disrupting the supply chain.
• Regulatory Authorities: Ongoing interactions with the FDA and EMA for clinical trial design and approval, requiring strict compliance with extensive regulations. Changes in regulatory policies or interpretations could impact development timelines and costs.

Next Steps

• Top-line results for the COG0203 (START) Phase 2 study in MCI and early-stage AD are expected after all participants complete 18 months of treatment.
• The company plans to develop zervimesine for DLB psychosis.
• Planning to meet with the FDA Division of Psychiatry to discuss a DLB psychosis program and align on study design.
• Proposed plans for a Phase 3 program for zervimesine in mild-to-moderate AD, with FDA concurrence on design (100 mg oral zervimesine daily for at least six months, enrich with lower plasma p-tau217 patients).
• Evaluating additional product candidates and bringing forward novel chemical matter using proprietary molecule generation and screening strategies.
• May supplement internal development through selective in-licensing arrangements, strategic collaborations, and partnerships.
• Plan to develop and pursue approval of zervimesine in major markets, potentially using strategic collaborations or partnerships.
• Intend to continue pursuing non-dilutive funding opportunities, including additional NIA grant funding.
• Will transition from current drug product manufacturer to a larger third-party manufacturer for late-stage clinical and commercial supply.
• Must either develop a sales and marketing infrastructure or collaborate with third parties to commercialize any approved products.
• Will need to expand managerial, operational, finance, and other resources to manage operations and clinical trials.
• Will need to hire additional personnel as clinical development expands and if commercial activities are initiated.
• Expects to expand product liability insurance coverage upon marketing approval of any product candidates.
• Will continue to derive expected volatility from average historical stock volatilities of industry peers until sufficient trading history is compiled.
• An assessment to determine whether a Section 382 ownership change occurred during 2025 has not been completed.

Key Dates

Recommendation

Cognition Therapeutics presents a high-risk, high-reward profile. While zervimesine shows promising early clinical efficacy signals in AD and DLB, addressing significant unmet medical needs, the company remains in early clinical stages with no approved products and faces substantial financial challenges, including recurring losses and a stated need for significant additional capital. The strategic decision to discontinue the AMD program, despite positive data, underscores resource constraints. The long and uncertain path to regulatory approval and commercialization, coupled with market volatility and intense competition, suggests a 'hold' recommendation for seasoned investors, awaiting further de-risking through advanced clinical trial results and a clearer path to sustainable funding.

Keywords

Biopharmaceutical, Neurodegenerative Diseases, Alzheimer's Disease, Dementia with Lewy Bodies, Zervimesine, CT1812, Clinical Trials, Phase 2, FDA Fast Track, Small Molecule, Synaptoprotective, NIA Grants, Drug Development, Intellectual Property, Geographic Atrophy, Dry AMD, α-synuclein, Aβ oligomers, Nasdaq